Breathlessness mystery: can a finger device predict side effects in myeloma treatment?

NCT ID NCT04827563

Terminated Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to find out why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved finger device called EndoPAT to check blood vessel health and tracked symptoms through surveys. The study enrolled 50 adults with newly diagnosed or relapsed multiple myeloma who were already receiving carfilzomib. The goal was to gather information to better prevent this side effect in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib
What this could lead to: If successful, this could help doctors predict and prevent shortness of breath in multiple myeloma patients receiving carfilzomib.
What could go wrong: This is a small, terminated pilot study, so results may be limited. It does not test a new treatment, only gathers information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cardiotoxicity Dyspnea plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOTOXICITY DYSPNEA MULTIPLE MYELOMA SHORTNESS OF BREATH

Contacts and locations

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.